Benlysta (belimumab) – Updated dosing
June 24, 2025 - GSK announced the FDA approval of the subcutaneous (SC) autoinjector formulation of Benlysta (belimumab), for the treatment of patients 5 years of age and older with active lupus nephritis (LN) who are receiving standard therapy.
Download PDF